About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.
2018 Juristant Badge - MBHB_165
Juristat #4 Overall Rank

E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.

Contact the Docs

Docs on Twitter


  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.
Juristat #8 Overall Rank


« USPTO News: Pilot Program to Allow Law Students to Practice before the Office | Main | USPTO News: Patent Office Launches Financial Profile System »

April 17, 2008


I think you've got your indications mixed up - I know Copaxone is used for MS, and I'm pretty sure the article said that Tykerb was for breast cancer.

Dear Elizabeth:

Exactly right. Probably the editor's fault. We will fix it. Thanks for the comment.

You still have an editing problem...

Copaxone is glatiramer acetate and Tykerb is lapatinib ditosylate.

Never mind the little errors, who's gonna fix the drug prices so senior citizens can afford them?

Dear Gayle:

We need a balance between enough profit to promote investment to support R&D, and cheap enough prices so that folks who can't afford high priced drugs get what they need.

I certainly think a senior citizen who is a millionaire (like George Soros or T. Boone Pickens or Ross Perot) needs to be treated differently than the pensioner living down the street. That's the problem with "one size fits all" solutions - they don't work. But the other kind require the type of political will that is hard to come by.

Martin Gardener (I think) had a piece in The New Yorker recently about how France and England developed their national health services, and not surprisingly they both stemmed from the war years. I hope it won't take that kind of cataclysm for the U.S. to get its health care house in order.

Thanks for the comment.

The comments to this entry are closed.

March 2023

Sun Mon Tue Wed Thu Fri Sat
      1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31